{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:23:12Z","timestamp":1790623392705,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T00:00:00Z","timestamp":1502841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.lungcan.2017.08.005","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:31:09Z","timestamp":1502325069000},"page":"200-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":283,"special_numbering":"C","title":["PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review"],"prefix":"10.1016","volume":"112","author":[{"given":"Robert","family":"Brody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiduo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Kashif","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palvi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lungcan.2017.08.005_bib0005","first-page":"649","article-title":"The need for third-line treatment in non-small cell lung cancer: an overview of new options","volume":"31","author":"Syrigos","year":"2011","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2017.08.005_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.lungcan.2017.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2017.08.005_bib0020","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2017.08.005_bib0025","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0030","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/jco.2015.33.15_suppl.8034","article-title":"Avelumab ((MSB0010718C)), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy","volume":"33","author":"Gulley","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0035","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0040","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1200\/jco.2015.33.15_suppl.8028","article-title":"Clinical activity and safety from a phase II study (FIR) of atezolizumab (anti-PDL1) in PD-L1\u2013selected patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Spigel","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2017.08.005_bib0045","doi-asserted-by":"crossref","first-page":"B001","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-B001","article-title":"Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab","volume":"4","author":"Boyd","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0050","doi-asserted-by":"crossref","first-page":"11065","DOI":"10.1200\/jco.2015.33.15_suppl.11065","article-title":"Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC)","volume":"33","author":"Dolled-Filhart","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0055","unstructured":"Food and Drug Administration (FDA). Dako PD-L1 IHC 28-8 pharmDx. October 2015. Last accessed 10 August 20162015. Available from: http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150025c.pdf."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0060","unstructured":"Food and Drug Administration (FDA). Dako PD-L1 IHC 22C3 pharmDx. September 2015. Last accessed 10 August 20162015. Available from: http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150013c.pdf."},{"issue":"8","key":"10.1016\/j.lungcan.2017.08.005_bib0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0070","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/jco.2015.33.15_suppl.8033","article-title":"Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients","volume":"33","author":"Rebelatto","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2017.08.005_bib0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed death ligand 1 immunohistochemistry: friend or foe?","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2017.08.005_bib0080","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","volume":"3","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2017.08.005_bib0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non\u2013small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2017.08.005_bib0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5858\/arpa.2015-0506-SA","article-title":"Programmed death ligand 1 immunohistochemistry - a new challenge for pathologists: a perspective from members of the pulmonary pathology society","volume":"140","author":"Sholl","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2017.08.005_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"3","key":"10.1016\/j.lungcan.2017.08.005_bib0100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med. Oncol. (Northwood, Lond., Engl.)"},{"issue":"8","key":"10.1016\/j.lungcan.2017.08.005_bib0105","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.lungcan.2017.08.005_bib0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"468","author":"Ilie","year":"2016","journal-title":"Virchows Arch."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0115","unstructured":"Food and Drug Administration (FDA). VENTANA PD-L1 (SP142) Assay. Last accessed 10 January 20162016. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma_template.cfm?id=p160006."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0120","unstructured":"Ventana Medical Systems. Ventana PD-L1 (SP263) assay is a qualitative IHC assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue. Last accessed 19 May 2017. Available from: http:\/\/productlibrary.ventana.com\/ventana_portal\/OpenOverlayServlet?launchIndex=1&objectId=740-49071014737US."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0125","unstructured":"Ventana Medical Systems. VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the detection of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. It is indicated as an aid in the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types. Last accessed 19 May 2017. Available from: http:\/\/productlibrary.ventana.com\/ventana_portal\/OpenOverlayServlet?launchIndex=2&objectId=790-49051014247US."},{"issue":"2","key":"10.1016\/j.lungcan.2017.08.005_bib0130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2017.08.005_bib0135","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2017.08.005_bib0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab. Invest."},{"issue":"5","key":"10.1016\/j.lungcan.2017.08.005_bib0145","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.18632\/oncotarget.3097","article-title":"B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer","volume":"6","author":"Mao","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lungcan.2017.08.005_bib0150","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/1759-7714.12247","article-title":"Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics","volume":"6","author":"Zhang","year":"2015","journal-title":"Thorac. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2017.08.005_bib0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3892\/br.2012.10","article-title":"PD-L1 gene expression in Japanese lung cancer patients","volume":"1","author":"Sasaki","year":"2013","journal-title":"Biomed. Rep."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0160","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/jco.2015.33.15_suppl.8010","article-title":"Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0165","article-title":"Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)","volume":"51","author":"Besse","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0170","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1200\/jco.2015.33.15_suppl.8030","article-title":"Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum based doublet chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC)","volume":"15","author":"Liu","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7528","key":"10.1016\/j.lungcan.2017.08.005_bib0175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0180","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/jco.2015.33.15_suppl.3014","article-title":"Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC","volume":"33","author":"Antonia","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2017.08.005_bib0185","doi-asserted-by":"crossref","first-page":"B005","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-B005","article-title":"An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients","volume":"4","author":"Rebelatto","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0190","unstructured":"Ventana Medical Systems. Ventana PD-L1 (SP263) Assay. Last accessed 10 August 20162015. Available from: http:\/\/www.ventana.com\/product\/1815?type=2324."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0195","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1016\/S0959-8049(16)31668-9","article-title":"Prognostic value of PDL1 expression in stage III non-small cell lung cancer (NSCLC) treated by chemo-radiotherapy (CRT)","volume":"51","author":"Adam","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.08.005_bib0200","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/jco.2015.33.15_suppl.8012","article-title":"Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC)","volume":"33","author":"Gainor","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2017.08.005_bib0205","doi-asserted-by":"crossref","first-page":"14209","DOI":"10.18632\/oncotarget.3694","article-title":"The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0210","doi-asserted-by":"crossref","first-page":"LBA109","DOI":"10.1200\/jco.2015.33.18_suppl.lba109","article-title":"Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced nonsquamous cell (non-SQ) non-small cell lung cancer (NSCLC)","volume":"33","author":"Paz-Ares","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2017.08.005_bib0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0220","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/jco.2015.33.15_suppl.8009","article-title":"A phase III study (CheckMate 017) of nivolumab (NIVO; antiprogrammed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)","volume":"33","author":"Spigel","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.08.005_bib0225","article-title":"First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status","volume":"90","author":"Rizvi","year":"2014","journal-title":"Int. J. Rad. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0230","doi-asserted-by":"crossref","first-page":"S632","DOI":"10.1016\/S0959-8049(16)31737-3","article-title":"First-line nivolumab monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and biomarker analyses","volume":"51","author":"Gettinger","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0235","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1200\/jco.2015.33.15_suppl.8025","article-title":"First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0240","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1200\/jco.2014.32.15_suppl.8024","article-title":"First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status","volume":"32","author":"Gettinger","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.08.005_bib0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2017.08.005_bib0250","first-page":"S57","article-title":"Nivolumab exposure-response (E-R) analysis for clinical development of nivolumab in advanced refractory squamous non-small cell lung cancer","volume":"97","author":"Feng","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2017.08.005_bib0255","article-title":"Phase 2 study of nivolumab (anti-programmed death-1 [PD-1]) in patients (pts) with advanced, refractory squamous (SQ) non-small cell lung cancer (NSCLC)","volume":"26","author":"Zalcman","year":"2015","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2017.08.005_bib0260","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0265","article-title":"Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (anti-PD-1; BMS- 936558; ONO-4538)","volume":"8","author":"Antonia","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl.2","key":"10.1016\/j.lungcan.2017.08.005_bib0270","article-title":"Nivolumab (anti-PD-1; BMS-936558; ONO- 4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial","volume":"8","author":"Brahmer","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0275","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1200\/jco.2014.32.15_suppl.8112","article-title":"Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis","volume":"32","author":"Brahmer","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1 (4)","key":"10.1016\/j.lungcan.2017.08.005_bib0280","article-title":"Clinical activity, safety and subpopulation response analysis of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (PT) with non-small cell lung cancer (NSCLC)","volume":"9","author":"Brahmer","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0285","first-page":"S909","article-title":"Efficacy of nivolumab (anti-PD-1; BMS- 936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC): subpopulation response analysis in a phase 1 trial","volume":"8","author":"Gettinger","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.08.005_bib0290","article-title":"Long-term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients (PTS) with advanced non-small cell lung cancer (NSCLC)","volume":"90","author":"Gettinger","year":"2014","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0295","first-page":"S185","article-title":"Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538)","volume":"49","author":"Hodi","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0300","first-page":"S152","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis","volume":"9","author":"Rizvi","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"26","key":"10.1016\/j.lungcan.2017.08.005_bib0305","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0310","article-title":"Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)","volume":"51","author":"Hellmann","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.lungcan.2017.08.005_bib0315","first-page":"155","article-title":"Nivolumab and ipilimumab in first-line non-small-cell lung carcinoma (NSCLC): interim phase I results","volume":"10","author":"Antonia","year":"2014","journal-title":"Asia-Pac. J. Clin. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.08.005_bib0320","article-title":"Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC): metastatic non-small cell lung cancer","volume":"90","author":"Antonia","year":"2014","journal-title":"Int. J. Rad. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0325","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1200\/jco.2014.32.15_suppl.8023","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results","volume":"32","author":"Antonia","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0330","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.1200\/jco.2014.32.15_suppl.8020","article-title":"Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC)","volume":"32","author":"Garon","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0335","doi-asserted-by":"crossref","first-page":"CT104","DOI":"10.1158\/1538-7445.AM2015-CT104","article-title":"Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: findings from KEYNOTE-001","volume":"75","author":"Garon","year":"2015","journal-title":"Cancer Res."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0340","article-title":"Efficacy and safety of pembrolizumab (pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in Keynote-001","volume":"51","author":"Soria","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"6230","key":"10.1016\/j.lungcan.2017.08.005_bib0345","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"5 Suppl","key":"10.1016\/j.lungcan.2017.08.005_bib0350","article-title":"Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"90","author":"Balmanoukian","year":"2014","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0355","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/jco.2014.32.15_suppl.8007","article-title":"Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"32","author":"Rizvi","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0360","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1200\/jco.2015.33.15_suppl.8035","article-title":"Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases","volume":"33","author":"Goldberg","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 4","key":"10.1016\/j.lungcan.2017.08.005_bib0365","first-page":"iv 457","article-title":"PD-L1 expression and survival among advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy","volume":"25","author":"Sorensen","year":"2014","journal-title":"Ann. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0370","article-title":"Molecular correlates of PD- status and predictive biomarkers in patients with non-small cell lung cancer (NSCLC) treated with the anti-PDL1 antibody MPDL3280A","volume":"8","author":"Gettinger","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0375","first-page":"S364","article-title":"An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PD-L1)","volume":"8","author":"Horn","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0380","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/jco.2015.33.15_suppl.8029","article-title":"Clinical activity, safety and predictive biomarkers of the engineered antibody atezolizumab (MPDL3280A, anti-PD-L1) in non-small cell lung cancer (NSCLC): update from a phase Ia study","volume":"33","author":"Horn","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0385","first-page":"S798","article-title":"Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PD-L1)","volume":"49","author":"Soria","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0390","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/jco.2013.31.15_suppl.8008","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)","volume":"31","author":"Spigel","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0395","doi-asserted-by":"crossref","first-page":"S602","DOI":"10.1016\/S0959-8049(16)31661-6","article-title":"NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents distinct cancer subtypes","volume":"51","author":"Schmid","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0400","article-title":"Atezolizumab monotherapy vs docetaxel in 2L\/3L non-small cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)","volume":"51","author":"Vansteenkiste","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0405","article-title":"High tumoral IFN\u03b3 mRNA, PD-L1 protein, and combined IFN\u03b3 mRNA\/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients","volume":"51","author":"Higgs","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2017.08.005_bib0410","doi-asserted-by":"crossref","first-page":"B004","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-B004","article-title":"The importance of quality standards to support test performance for the purpose of treatment decision making","volume":"4","author":"Midha","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0415","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1016\/S0959-8049(16)31727-0","article-title":"A phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC","volume":"51","author":"Goldberg","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. (15)","key":"10.1016\/j.lungcan.2017.08.005_bib0420","doi-asserted-by":"crossref","first-page":"e19137","DOI":"10.1200\/jco.2014.32.15_suppl.e19137","article-title":"A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti\u2013PD-L1 antibody, in combination with tremelimumab in subjects with advanced non\u2013small cell lung cancer","volume":"32","author":"Pinder","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2017.08.005_bib0425","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.1016\/S0959-8049(16)31731-2","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: a phase Ib trial","volume":"51","author":"Gulley","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0430","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1200\/jco.2015.33.15_suppl.7542","article-title":"Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients who received concurrent chemoradiotherapy","volume":"33","author":"Tokito","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0435","article-title":"Programmed cell death-1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in Chinese stage III\/IV lung squamous lung carcinoma (SQC)","volume":"33","author":"Wang","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2017.08.005_bib0440","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'Incecco","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.lungcan.2017.08.005_bib0445","article-title":"PD- and PD-1 expression in molecularly selected non-small cell lung cancer (NSCLC) patients","volume":"9","author":"D'Incecco","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2017.08.005_bib0450","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cllc.2015.02.002","article-title":"Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma","volume":"16","author":"Lin","year":"2015","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2017.08.005_bib0455","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/030089161209800612","article-title":"Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study","volume":"98","author":"Chen","year":"2012","journal-title":"Tumori"},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.005_bib0460","first-page":"163","article-title":"Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study","volume":"16","author":"Chen","year":"2011","journal-title":"Respirology"},{"issue":"Suppl. 3 (9)","key":"10.1016\/j.lungcan.2017.08.005_bib0465","first-page":"L1","article-title":"PD expression in metastatic non-small cell lung cancer patients from Colombia (CLICAP)","volume":"9","author":"Rojas","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"S1","key":"10.1016\/j.lungcan.2017.08.005_bib0470","article-title":"PD-L1 expression in stage IV lung cancer","volume":"94","author":"Sun","year":"2014","journal-title":"Lab. Invest."},{"issue":"S1","key":"10.1016\/j.lungcan.2017.08.005_bib0475","article-title":"Tumor infiltrating lymphocytes are associated with epithelial expression of PD-L1 protein, PD-L1 mRNA and better outcome in non-small cell lung cancer","volume":"94","author":"Schalper","year":"2014","journal-title":"Lab. Invest."},{"issue":"Suppl. 15","key":"10.1016\/j.lungcan.2017.08.005_bib0480","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1200\/jco.2013.31.15_suppl.11075","article-title":"Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer NSCLC)","volume":"31","author":"Velcheti","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2017.08.005_bib0485","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"Suppl","key":"10.1016\/j.lungcan.2017.08.005_bib0490","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2016.34.15_suppl.3001","article-title":"CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC","volume":"34","author":"Hellmann","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2017.08.005_bib0495","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tranon.2016.01.003","article-title":"PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy","volume":"9","author":"Sorensen","year":"2016","journal-title":"Transl. Oncol."},{"issue":"10030","key":"10.1016\/j.lungcan.2017.08.005_bib0500","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2017.08.005_bib0505","series-title":"2nd AstraZeneca-MedImmune Cambridge Cancer Science Symposium","article-title":"Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","author":"Segal","year":"2015"},{"issue":"Suppl","key":"10.1016\/j.lungcan.2017.08.005_bib0510","doi-asserted-by":"crossref","first-page":"9025","DOI":"10.1200\/JCO.2016.34.15_suppl.9025","article-title":"Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017\/057 2-y update and exploratory cytokine profile analyses","volume":"34","author":"Borghaei","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.08.005_bib0515","first-page":"462","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis","volume":"7","author":"Pan","year":"2015","journal-title":"J. Thoracic Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2017.08.005_bib0520","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2017.08.005_bib0525","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.lungcan.2017.08.005_bib0530","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2017.08.005_bib0535","doi-asserted-by":"crossref","first-page":"e1094598","DOI":"10.1080\/2162402X.2015.1094598","article-title":"Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1\/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients","volume":"5","author":"Hong","year":"2016","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1016\/j.lungcan.2017.08.005_bib0540","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2017.08.005_bib0545","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.lungcan.2015.06.005","article-title":"PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis","volume":"4","author":"Zhou","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0550","first-page":"2617","article-title":"The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis","volume":"8","author":"Huang","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"9","key":"10.1016\/j.lungcan.2017.08.005_bib0555","first-page":"14595","article-title":"Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2017.08.005_bib0560","doi-asserted-by":"crossref","first-page":"e0131403","DOI":"10.1371\/journal.pone.0131403","article-title":"PD-L1 and survival in solid tumors: a meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"issue":"10027","key":"10.1016\/j.lungcan.2017.08.005_bib0565","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2017.08.005_bib0570","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5858\/2010-0702-RAIR.1","article-title":"Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue","volume":"135","author":"Engel","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2017.08.005_bib0575","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.5858\/arpa.2014-0074-RA","article-title":"Standardization of diagnostic immunohistochemistry: literature review and geisinger experience","volume":"138","author":"Lin","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.lungcan.2017.08.005_bib0580","unstructured":"D.B. Doroshow, R.B. Herbst. Pembrolizumab as first-line therapy in metastatic NSCLC: practice-changing implications of KEYNOTE-024 trial ASCO Post. 25 2016. Last accessed 10 January 20172016. Available from: http:\/\/www.ascopost.com\/issues\/november-25-2016\/pembrolizumab-as-first-line-therapy-in-metastatic-nsclc-practice-changing-implications-of-keynote-024-trial\/."},{"issue":"2","key":"10.1016\/j.lungcan.2017.08.005_bib0585","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.lungcan.2017.08.005_bib0590","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","article-title":"Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis","volume":"45","author":"Zhang","year":"2008","journal-title":"Mol. Immunol."},{"issue":"7","key":"10.1016\/j.lungcan.2017.08.005_bib0595","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2017.08.005_bib0600","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2017.08.005_bib0605","doi-asserted-by":"crossref","first-page":"e89014","DOI":"10.1172\/jci.insight.89014","article-title":"Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes","volume":"1","author":"Lizotte","year":"2016","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.lungcan.2017.08.005_bib0610","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.2015.63.8049","article-title":"Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition","volume":"34","author":"Melosky","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.08.005_bib0615","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T19:57:56Z","timestamp":1659297476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217304440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":123,"alternative-id":["S0169500217304440"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AstraZeneca LP. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}